Study identifies potential target for reversing drug resistance in ovarian cancer
For the 314,000 people diagnosed with ovarian cancer each year, hope often comes in the form of platinum-based drugs such as cisplatin. Cisplatin causes the death of quick-dividing tumour cells, so it is a potent first-line defence in the treatment of the often fatal disease. However, over half of ovarian cancer patients develop recurrence and … Read more
